Literature DB >> 18523483

Downregulation of integrins by von Hippel-Lindau (VHL) tumor suppressor protein is independent of VHL-directed hypoxia-inducible factor alpha degradation.

Qingzhou Ji1, Robert D Burk.   

Abstract

Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene occurs in the majority of clear-cell renal cell carcinomas (RCCs). It was previously shown that VHL decreased the abundance of integrins alpha2, alpha5, and beta1, which is consistent with VHL-associated changes in cell-cell and cell - extracellular matrix adhesions. We investigated the mechanism by which VHL downregulates integrins. Although VHL can target hypoxia-inducible factor alpha (HIFalpha) subunits for degradation, VHL-dependent reduction of integrins was independent of O2 concentration and HIFalpha levels. VHL reduced the half-lives of integrins, and this activity was blocked by proteasomal inhibition. Although ectopically expressed FLAG-VHL retained HIFalpha degradation activity, it neither downregulated integrins nor promoted adherens and tight intercellular junctions, in contrast to expressed wild-type VHL. Moreover, integrins co-immunoprecipitated with wild-type VHL, but not FLAG-VHL. These data indicate that the downregulation of integrins by VHL is distinct from the regulation of HIFalpha subunits by VHL, and suggests that the loss of this activity contributes to VHL-associated RCC development through disruption of adherens and tight junctions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523483      PMCID: PMC3708035          DOI: 10.1139/o08-035

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  33 in total

Review 1.  Integrin signaling.

Authors:  F G Giancotti; E Ruoslahti
Journal:  Science       Date:  1999-08-13       Impact factor: 47.728

Review 2.  Role of VHL gene mutation in human cancer.

Authors:  William Y Kim; William G Kaelin
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

3.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

4.  von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.

Authors:  Maria J Calzada; Miguel A Esteban; Monica Feijoo-Cuaresma; Maria C Castellanos; Salvador Naranjo-Suárez; Elisa Temes; Fernando Méndez; Maria Yánez-Mo; Michael Ohh; Manuel O Landázuri
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

5.  Integrins regulate VE-cadherin and catenins: dependence of this regulation on Src, but not on Ras.

Authors:  Yingxiao Wang; Gang Jin; Hui Miao; Julie Y-S Li; Shunichi Usami; Shu Chien
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-30       Impact factor: 11.205

6.  Regulation of E-cadherin expression by VHL and hypoxia-inducible factor.

Authors:  Miguel A Esteban; Maxine G B Tran; Sarah K Harten; Peter Hill; Maria C Castellanos; Ashish Chandra; Raju Raval; Tim S O'brien; Patrick H Maxwell
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

7.  Expression of the Von Hippel-Lindau tumor suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis.

Authors:  P M Kessler; S P Vasavada; R R Rackley; T Stackhouse; F M Duh; F Latif; M I Lerman; B Zbar; B R Williams
Journal:  Mol Med       Date:  1995-05       Impact factor: 6.354

8.  The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix.

Authors:  M Ohh; R L Yauch; K M Lonergan; J M Whaley; A O Stemmer-Rachamimov; D N Louis; B J Gavin; N Kley; W G Kaelin; O Iliopoulos
Journal:  Mol Cell       Date:  1998-06       Impact factor: 17.970

9.  Tumour suppression by the human von Hippel-Lindau gene product.

Authors:  O Iliopoulos; A Kibel; S Gray; W G Kaelin
Journal:  Nat Med       Date:  1995-08       Impact factor: 53.440

10.  A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor.

Authors:  A Schoenfeld; E J Davidowitz; R D Burk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more
  6 in total

Review 1.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

Review 2.  Par complex in cancer: a regulator of normal cell polarity joins the dark side.

Authors:  V Aranda; M E Nolan; S K Muthuswamy
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

Review 3.  VHL, the story of a tumour suppressor gene.

Authors:  Lucy Gossage; Tim Eisen; Eamonn R Maher
Journal:  Nat Rev Cancer       Date:  2015-01       Impact factor: 60.716

Review 4.  The Extracellular Matrix Environment of Clear Cell Renal Cell Carcinoma.

Authors:  Leif Oxburgh
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

5.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

6.  Bilateral Pheochromocytomas in a Patient with Y175C Von Hippel-Lindau Mutation.

Authors:  Olga Astapova; Anindita Biswas; Alessandra DiMauro; Jacob Moalem; Stephen R Hammes
Journal:  Case Rep Endocrinol       Date:  2018-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.